This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinicaltrials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Lancet Neurol Dec 23 2015. Fabricio A.
Virpax recently acquired global rights to VRP324, a product candidate for the intranasal delivery of a pharmaceutical-grade Schedule V cannabidiol (CBD) for the management of epilepsy in children, a rare pediatric disease. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the 16 years.
Alas, Mr. Gardner wrote in 2005, that would require access to expensive testing equipment. fast-tracked clinicaltrials of GW Pharmaceuticals’ 98 percent CBD drug, Epidiolex. There haven’t been enough clinicaltrials and there never will be,” said Mr. Clarke, the cannabis seed collector.
Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Refractory paediatric epilepsy. Conclusions. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ).
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content